Johnson & Johnson (JNJ)vsRevvity Inc. (RVTY)
JNJ
Johnson & Johnson
$224.62
-0.41%
HEALTHCARE · Cap: $546.90B
RVTY
Revvity Inc.
$99.09
+7.36%
HEALTHCARE · Cap: $9.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3274% more annual revenue ($96.36B vs $2.86B). JNJ leads profitability with a 21.8% profit margin vs 8.4%. RVTY appears more attractively valued with a PEG of 0.53. RVTY earns a higher WallStSmart Score of 63/100 (C+).
JNJ
Buy59
out of 100
Grade: C
RVTY
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.3%
Fair Value
$160.72
Current Price
$224.62
$63.90 premium
Margin of Safety
+7.8%
Fair Value
$109.59
Current Price
$99.09
$10.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.1%
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
ROE of 3.2% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : RVTY
The strongest argument for RVTY centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : RVTY
The primary concerns for RVTY are Return on Equity, P/E Ratio. A P/E of 42.1x leaves little room for execution misses.
Key Dynamics to Monitor
JNJ profiles as a mature stock while RVTY is a value play — different risk/reward profiles.
RVTY carries more volatility with a beta of 1.13 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
RVTY scores higher overall (63/100 vs 59/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Revvity Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?